“Sell an Ox”-The Price of Cure for Hepatitis C in Two Countries

Ora Paltiel; Workagegnehu Hailu; Zenahebezu Abay; Avram Mark Clarfield; Martin McKee

doi:10.15171/ijhpm.2019.135

“Sell an Ox”-The Price of Cure for Hepatitis C in Two Countries

Ora Paltiel, Workagegnehu Hailu, Zenahebezu Abay, Avram Mark Clarfield, Martin McKee

Medical School for International Health

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Chronic hepatitis C virus (HCV) infection, associated with severe liver disease and cancer, affects 70 million people worldwide. New treatments with direct-acting-antivirals offer cure for about 95% of affected individuals; however, treatment costs may be prohibitive in both the poorest and richest nations. Opting for cure may require sacrificing essential household assets. We highlight the financial dilemmas involved, drawing parallels between Ethiopia and the United States, countries where universal health coverage does not yet exist. The World Health Organization (WHO) declaration for HCV eradication by 2030 will only become reality if universal access to efficacious and affordable treatment is guaranteed for everyone.

Original language	English
Pages (from-to)	229-232
Number of pages	4
Journal	International Journal of Health Policy and Management
Volume	9
Issue number	6
DOIs	https://doi.org/10.15171/ijhpm.2019.135
State	Published - 1 Jun 2020

Keywords

Antiviral Therapy
Ethiopia
Hepatitis C
Out-of-Pocket Expenses
USA

ASJC Scopus subject areas

Leadership and Management
Health(social science)
Health Policy
Management, Monitoring, Policy and Law
Health Information Management

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.15171/ijhpm.2019.135

Cite this

@article{bb10e7b1bbe041f6a774121d249ef6fc,

title = "“Sell an Ox”-The Price of Cure for Hepatitis C in Two Countries",

abstract = "Chronic hepatitis C virus (HCV) infection, associated with severe liver disease and cancer, affects 70 million people worldwide. New treatments with direct-acting-antivirals offer cure for about 95% of affected individuals; however, treatment costs may be prohibitive in both the poorest and richest nations. Opting for cure may require sacrificing essential household assets. We highlight the financial dilemmas involved, drawing parallels between Ethiopia and the United States, countries where universal health coverage does not yet exist. The World Health Organization (WHO) declaration for HCV eradication by 2030 will only become reality if universal access to efficacious and affordable treatment is guaranteed for everyone.",

keywords = "Antiviral Therapy, Ethiopia, Hepatitis C, Out-of-Pocket Expenses, USA",

author = "Ora Paltiel and Workagegnehu Hailu and Zenahebezu Abay and Clarfield, {Avram Mark} and Martin McKee",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s).",

year = "2020",

month = jun,

day = "1",

doi = "10.15171/ijhpm.2019.135",

language = "English",

volume = "9",

pages = "229--232",

journal = "International Journal of Health Policy and Management",

issn = "2322-5939",

publisher = "Kerman University of Medical Sciences",

number = "6",

}

TY - JOUR

T1 - “Sell an Ox”-The Price of Cure for Hepatitis C in Two Countries

AU - Paltiel, Ora

AU - Hailu, Workagegnehu

AU - Abay, Zenahebezu

AU - Clarfield, Avram Mark

AU - McKee, Martin

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Chronic hepatitis C virus (HCV) infection, associated with severe liver disease and cancer, affects 70 million people worldwide. New treatments with direct-acting-antivirals offer cure for about 95% of affected individuals; however, treatment costs may be prohibitive in both the poorest and richest nations. Opting for cure may require sacrificing essential household assets. We highlight the financial dilemmas involved, drawing parallels between Ethiopia and the United States, countries where universal health coverage does not yet exist. The World Health Organization (WHO) declaration for HCV eradication by 2030 will only become reality if universal access to efficacious and affordable treatment is guaranteed for everyone.

AB - Chronic hepatitis C virus (HCV) infection, associated with severe liver disease and cancer, affects 70 million people worldwide. New treatments with direct-acting-antivirals offer cure for about 95% of affected individuals; however, treatment costs may be prohibitive in both the poorest and richest nations. Opting for cure may require sacrificing essential household assets. We highlight the financial dilemmas involved, drawing parallels between Ethiopia and the United States, countries where universal health coverage does not yet exist. The World Health Organization (WHO) declaration for HCV eradication by 2030 will only become reality if universal access to efficacious and affordable treatment is guaranteed for everyone.

KW - Antiviral Therapy

KW - Ethiopia

KW - Hepatitis C

KW - Out-of-Pocket Expenses

KW - USA

UR - http://www.scopus.com/inward/record.url?scp=85085029691&partnerID=8YFLogxK

U2 - 10.15171/ijhpm.2019.135

DO - 10.15171/ijhpm.2019.135

M3 - Article

C2 - 32613790

AN - SCOPUS:85085029691

SN - 2322-5939

VL - 9

SP - 229

EP - 232

JO - International Journal of Health Policy and Management

JF - International Journal of Health Policy and Management

IS - 6

ER -

“Sell an Ox”-The Price of Cure for Hepatitis C in Two Countries

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this